Moderately Hypofractionated Radiotherapy for Prostate Cancer.

Last updated: February 8, 2019
Sponsor: Tatarstan Cancer Center
Overall Status: Active - Enrolling

Phase

2

Condition

Prostate Disorders

Prostate Cancer

Urologic Cancer

Treatment

N/A

Clinical Study ID

NCT03827616
prostata116
  • Ages 18-100
  • Male

Study Summary

Radiation therapy is one of the standard treatments for men with prostate cancer. Moderately hypofractionated radiotherapy has been established to be equivalent to standard fractionated radiotherapy in several large randomized clinical trials, however different hypofractionated regimens have been used in these studies. The two most common hypofractionated regimens are 70 Gy in 28 fractions and 60 Gy in 20 fractions, both are considered standard of care, however it is not unknown which regimen is better in terms of effectiveness and toxicity. The aim of this randomized controlled clinical trial is to compare the two hypofractionated radiotherapy regimens using Helical Tomotherapy.

Eligibility Criteria

Inclusion

Inclusion criteria:

  1. Histologically confirmed adenocarcinoma of the prostate. 2 The presence of the followingstudies: TRUS of the prostate gland, pelvis MRI, OSG.

3 Histological evaluation of prostate biopsy with assignment of the Gleason index.

4 Clinical stage T1-3N0M0 (AJCC 7th edition). 5 ECOG performance status 0-1 6 Age limit 18years. 7 Patient consent to participate in a clinical study.

Exclusion

Exclusion criteria:

  1. Prior or concurrent lymphomatous/hematogenous malignancy or other invasive malignancyexcept nonmelanomatous skin cancer or any other cancer for which the patient has beencontinually disease-free for ≥ 5 years (e.g., carcinoma in situ of the bladder or oralcavity)

  2. Distatnt metastases.

  3. Metastases in the lymph nodes of prostate cancer.

  4. Radical prostatectomy or cryodestruction of the prostate gland in history.

  5. Radiation of a small pelvis in the anamnesis. Bilateral orchectomy history.

  6. Unstable angina and/or congestive heart failure requiring hospitalization within thepast 6 months, transmural myocardial infarction within the past 6 months, acutebacterial or fungal infection requiring IV antibiotics, chronic obstructive pulmonarydisease exacerbation or other respiratory illness requiring hospitalization orprecluding study treatment, hepatic insufficiency resulting in clinical jaundiceand/or coagulation defects.

Study Design

Total Participants: 200
Study Start date:
January 25, 2019
Estimated Completion Date:
February 01, 2030

Study Description

OBJECTIVES:

Primary

Compare the biochemical relapse free survival (DFS) of patients with prostate cancer treated with hypofractionated regimens 70 Gy in 28 fractions and 60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.

Secondary

Compare time to local progression, freedom from biochemical recurrence, and disease-specific and overall survival of patients treated with these regimens.

Determine the incidence of gastrointestinal and genitourinary toxic effects in patients treated with these regimens.

OUTLINE: This is a randomized study. Patients are stratified according to TNM ( T1-3N0M0), Gleason score (6,7 (3+4), 7(4+3), 8). Before radiotherapy patients receive hormone therapy from 3 months to 6 months. Patients are randomized to 1 of 2 treatment arms.

Arm 1 hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula> 15% or N1) 28 x 1,8 Gy

  • 50,4 Gy).

Arm II hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).

After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Connect with a study center

  • Tatarstan Cancer Cente

    Kazan, Tatarstan 420029
    Russian Federation

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.